Factor XI and factor XII as targets for new anticoagulants

Thrombosis Research

Volumn 141, Issue , 2016, Pages S40-S45

  Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; contact system; factor XI; factor XII; intrinsic pathway; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; ENOXAPARIN; ANTIBODY; MOLECULAR LIBRARY;

ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 12 DEFICIENCY; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HUMAN; KNEE REPLACEMENT; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; PROCEDURES; THERAPEUTIC USE;

ANIMALS; ANTIBODIES; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; DRUG DISCOVERY; FACTOR XI; FACTOR XII; HUMANS; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; SMALL MOLECULE LIBRARIES; THROMBOSIS;

EID: 84989930205     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30363-2     Document Type: Article

References (47)

1. 1 Ruff, CT, Giugliano, RP, Braunwald, E, Hoffman, EB, Deenadayalu, N, Ezekowitz, MD, Camm, AJ, Weitz, JI, Lewis, BS, Parkhomenko, A, Yamashita, T, Antman, EM, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
2. 2 van der Hulle, T, Kooiman, J, den Exter, PL, Dekkers, OM, Klok, FA, Huisman, MV, Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J. Thromb. Haemost. 12 (2014), 320–328.
3. 3 Müller, F, Gailani, D, Renné, T, Factor XI and XII as antithrombotic targets. Curr. Opin. Hematol. 18 (2011), 349–355.
4. 4 Gailani, D, Bane, E, Gruber, A, Factor XI and contact activation as targets for antithombotic therapy. J. Thromb. Haemost. 13 (2015), 1383–1395.
5. 5 Salomon, O, Steinberg, DM, Zucker, M, Varon, D, Zivelin, A, Seligsohn, U, Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb. Haemost. 105 (2011), 269–273.
6. 6 Salomon, O, Steinberg, DM, Koren-Morag, N, Tanne, D, Seligsohn, U, Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111 (2008), 4113–4117.
7. 7 Renné, T, Pozgajová, M, Grüner, S, Schuh, K, Pauer, HU, Burfeind, P, Gailani, D, Nieswandt, B, Defective thrombus formation in mice lacking factor XII. J. Exp. Med. 202 (2005), 271–281.
8. 8 Renné, T, Oschatz, C, Seifert, S, Müller, F, Antovic, J, Karlman, M, Benz, PM, Factor XI deficiency in animal models. J. Thromb. Haemost. 7 (2009), 79–83.
9. 9 Smith, SA, Morrissey, JH, Polyphosphate; a new player in the field of hemostasis. Curr. Opin Hematol 21 (2014), 388–394.
10. 10 Kannemeier, C, Shibamiya, A, Nakazawa, F, Trusheim, H, Ruppert, C, Markart, P, Song, Y, Tzima, E, Kennerknecht, E, Niepmann, M, von Bruehl, M-L, Sedding, D, Massberg, S, Günther, A, Engelmann, B, Klaus, T, Preissner Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl. Acad. Sci. USA 104 (2007), 6388–6393.
11. 11 Fuchs, TA, Brill, A, Duerschmied, D, Schatzberg, D, Monestier, M, Myers, DD Jr, Wrobleski, SK, Wakefield, TW, Hartwig, JH, Wagner, DD, Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. USA. 107 (2010), 15880–15885.
12. 12 Gould, TJ, Vu, TT, Swystun, LL, Dwivedi, DJ, Mai, SH, Weitz, JI, Liaw, PC, Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1977–1984.
13. 13 Seligsohn, U, Factor XI deficiency in humans. J. Thromb. Hemost. 7 (2009), 84–87.
14. 14 Renne, T, The procoagulant and proinflammatory plasma contact system. Semin. Immunopathol. 34 (2012), 31–41.
15. 15 Schmaier, AH, Physiologic activities of the contact activation system. Thromb. Res. 133 (2014), S41–S44.
16. 16 Choi, SH, Smith, SA, Morrissey, JH, Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118 (2011), 6963–6970.
17. 17 Vu, TT, Leslie, BA, Stafford, AR, Zhou, J, Fredenburgh, JC, Weitz, JI, Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic pathway of coagulation. Thromb. Haemost., 115, 2015 Epub ahead of print.
18. 18 Meijers, JC, Tekelenburg, WL, Bouma, BN, Bertina, RM, Rosendaal, FR, High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342 (2000), 696–701.
19. 19 Cushman, M, O'Meara, ES, Folsom, AR, Heckbert, SR, Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114 (2009), 2878–2883.
20. 20 Siegerink, B, Govers-Riemslag, JW, Rosendaal, FR, Ten Cate, H, Algra, A, Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 122 (2010), 1854–1861.
21. 21 Doggen, CJ, Rosendaal, FR, Meijers, JC, Levels of instrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 108 (2006), 4045–4051.
22. 22 Salomon, O, Steinberg, DM, Dardik, R, Rosenberg, N, Zivelin, A, Tamarin, I, Ravid, B, Berliner, S, Seligsohn, U, Inherited factor XI deficiency confers no protection against acute myocardial infarction. J. Thromb. Haemost. 1 (2003), 658–661.
23. 23 Koster, T, Rosendaal, FR, Briet, E, Vandenbroucke, JP, John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br. J. Haematol. 87 (1994), 422–424.
24. 24 Zeerleder, S, Schloesser, M, Redondo, M, Wuillemin, WA, Engel, W, Furlan, M, Lammle, B, Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency – a study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82 (1999), 1240–1246.
25. 25 Cheng, Q, Tucker, EI, Pine, MS, Sisler, I, Matafonov, A, Sun, MF, White-Adams, TC, Smith, SA, Hanson, SR, McCarty, CJ, Renne, T, Gruber, A, Gailani, D, A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116 (2010), 3981–3989.
26. 26 Matafonov, A, Leung, PY, Gailani, AE, Grach, SL, Puy, C, Cheng, Q, Sun, MF, McCarty, CJ, Tucker, EI, Kataoka, H, Renne, T, Morissey, JH, Gruber, A, Gailani, D, Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 123 (2014), 1739–1746.
27. 27 Zhang, H, Lowenberg, EC, Crosby, JR, MacLeod, AR, Zhao, C, Gao, D, Black, C, Revenko, AS, Meijers, JC, Stroes, ES, Levi, M, Monia, BP, Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116 (2010), 4684–4692.
28. 28 Yau, JW, Liao, P, Fredenburgh, JC, Stafford, AR, Revenko, AS, Monia, BP, Weitz, JI, Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123 (2014), 2102–2107.
29. 29 Crosby, JR, Marzec, U, Revenko, AS, Zhao, C, Gao, D, Matafonov, A, Gailani, D, MacLeod, AR, Tucker, EI, Gruber, A, Hanson, SR, Monia, BP, Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1670–1678.
30. 30 Tucker, EI, Marzec, UM, White, TC, Hurst, S, Rugonyi, S, McCarty, OJ, Gailani, D, Gruber, A, Hanson, SR, Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 113 (2009), 936–944.
31. 31 Woodruff, RS, Xu, Y, Layzer, J, Wu, W, Ogletree, ML, Sullenger, BA, Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J. Thromb. Haemost. 11 (2013), 1364–1373.
32. 32 Deng, H, Bannister, TD, Jin, L, Babine, RE, Quinn, J, Nagafuji, P, Celatka, CA, Lin, J, Lazarova, TI, Rynkiewicz, MJ, Bibbins, F, Pandey, P, Gorga, J, Meyers, HV, Abdel-Meguid, SS, Strickler, JE, Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole argi-nine. Bioorg. Med. Chem. Lett. 16 (2006), 3049–3054.
33. 33 Wong, PC, Crain, EJ, Watson, CA, Schumacher, WA, A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J. Thromb. Thrombolysis 32 (2011), 129–137.
34. 34 Quan, ML, Wong, PC, Wang, C, Woerner, F, Smallheer, JM, Barbera, FA, Bozarth, JM, Brown, RL, Harpel, MR, Luettgen, JM, Morin, PE, Peterson, T, Ramamurthy, V, Rendina, AR, Rossi, KA, Watson, CA, Wei, A, Zhang, G, Seiffert, D, Wexler, RR, Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J. Med. Chem. 57 (2014), 955–969.
35. 35 Al-Horani, RA, Ponnusamy, P, Mehta, AY, Gailani, D, Desai, UR, Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J. Med. Chem. 56 (2013), 867–878.
36. 36 Al-Horani, RA, Desai, UR, Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J. Med. Chem. 57 (2014), 4805–4818.
37. 37 Gailani, D, Broze, GJ Jr, Factor XI activation in a revised model of blood coagulation. Science 253 (1999), 909–912.
38. 38 Jaffer, IH, Fredenburgh, JC, Hirsh, J, Weitz, JI, Medical device-induced thrombosis: what causes it and how can we prevent it?. J. Thromb. Haemost. 13 (2015), S72–S81.
39. 39 Yau, JW, Stafford, AR, Liao, P, Fredenburgh, JC, Roberts, R, Brash, JL, Weitz, JI, Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater 8 (2012), 4092–4100.
40. 40 Larsson, M, Rayzman, V, Nolte, MW, Nickel, KF, Bjorkqvist, J, Jamsa, A, Hardy, MP, Fries, M, Schmidbauer, S, Hedenqvist, P, Broome, M, Pragst, I, Dickneite, G, Wilson, MJ, Nash, AD, Panousis, C, Renne, T, A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci. Transl. Med., 6, 2014, 222 17.
41. 41 Jaffer, I, Stafford, AR, Fredenburgh, JC, Whitlock, RP, Chan, NC, Weitz, JI, Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J. Amer. Heart Assoc, 4, 2015 Aug 24.
42. Rx, a novel and specific antisense inhibitor of factor XI, caused a significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood, 118, 2011 Abst.#209.
43. 43 Buller, HR, Bethune, C, Bhanot, S, Gailani, D, Monia, BP, Raskob, GE, Segers, A, Verhamme, P, Weitz, JI, FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372 (2015), 232–240.
44. 44 Kearon, C, Natural history of venous thromboembolism. Circulation 107 (2003), I22–I30.
45. 45 Eikelboom, JW, Connolly, SJ, Brueckmann, M, Granger, CB, Kappetein, AP, Mack, MJ, Blatchford, J, Devenny, K, Friedman, J, Guiver, K, Harper, R, Khder, Y, Lobmeyer, MT, Maas, H, Voigt, JJ, Simoons, ML, Van de Werf, F, RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 369 (2013), 1206–1214.
46. 46 Mega, JL, Braunwald, E, Wiviott, SD, Bassand, JP, Bhatt, DL, Bode, C, Burton, P, Cohen, M, Cook-Bruns, N, Fox, KA, Goto, S, Murphy, SA, Plotnikov, AN, Schneider, D, Sun, X, Verheugt, FW, Gibson, CM, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366 (2012), 9–19.
47. 47 Weitz, JI, Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost 112 (2014), 924–931.